Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 70Squamous Cell Carcinoma of Head and Neck 32Parkinson Disease 4, Autosomal Dominant Lewy Body 30Lung Neoplasms 28Melanoma 24Triple Negative Breast Neoplasms 23Neoplasms 20Neoplasm Metastasis 20Breast Neoplasms 19Colorectal Neoplasms 18Head and Neck Neoplasms 15Endometrial Neoplasms 15Ovarian Neoplasms 14Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 11Carcinoma, Transitional Cell 10Pancreatic Neoplasms 7Hodgkin Disease 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Recurrence 6Lymphoma 6Carcinoma 6Stomach Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Mouth Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × pembrolizumab × 30 days × Clear all
NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡